NCT03980223View on ClinicalTrials.gov

Evaluation of Doxycycline Post-exposure Prophylaxis to Reduce Sexually Transmitted Infections in PrEP Users and HIV-infected Men Who Have Sex With Men

PHASE4CompletedINTERVENTIONAL
Enrollment

641

Participants

Timeline

Start Date

November 26, 2019

Primary Completion Date

June 12, 2023

Study Completion Date

June 12, 2023

Conditions
GonorrheaChlamydiaSyphilis
Interventions
DRUG

Doxycycline Hyclate Delayed-Release 200 mg

200 mg of doxycycline taken by mouth after condomless sexual contact as post exposure prophylaxis (PEP)

Trial Locations (3)

94103

San Francisco City Clinic / San Francisco Department of Public Health, San Francisco

94110

University of California, San Francisco / Zuckerberg San Francisco General Hospital/UCSF, San Francisco

98195

University of Washington, Seattle

All Listed Sponsors
collaborator

University of Washington

OTHER

collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

collaborator

Mayne Pharma International Pty Ltd

INDUSTRY

collaborator

San Francisco Department of Public Health

OTHER_GOV

lead

University of California, San Francisco

OTHER

NCT03980223 - Evaluation of Doxycycline Post-exposure Prophylaxis to Reduce Sexually Transmitted Infections in PrEP Users and HIV-infected Men Who Have Sex With Men | Biotech Hunter | Biotech Hunter